Catalyst Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 04/26/2024
Catalyst Pharmaceuticals Stock Forecast and Price Target
If Catalyst Pharmaceuticals's stock price reached the average yearlong target of $26.00 given by two well-known analysts in recent months, there would be a potential upside of approximately 77.11% from its last closing price in April, 2024. This potential increase is based on a high estimate of $34.00 and a low estimate of $22.00. If you want to buy CPRX stock, it might be a good idea to look at its competitors too.
77.11% Upside
Catalyst Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Catalyst Pharmaceuticals's Price has decreased from $6.21 to $0.00 – a 100.00% drop. For next year, analysts predict Fair Value of $22.98, which would mean an increase of 100.00%. Over the next seven years, experts predict that Catalyst Pharmaceuticals's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$724.87 | Buy/Sell | $636.99 | 15.54% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$146.82 | Buy/Sell | $174.55 | 15.79% |
| MRK Stock Forecast | Merck | Outperform |
2
|
$130.72 | Buy/Sell | $130.51 | 7.10% |
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$25.26 | Buy/Sell | $32.87 | 20.74% |
| VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
12
|
$397.70 | Buy/Sell | $457.59 | 13.15% |
Catalyst Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Catalyst Pharmaceuticals's Revenue has grown by 234.43%, rising from $119.07M to $398.20M. For next year, analysts predict Revenue of $462.44M, which would mean an increase of 16.13%. Over the next seven years, experts predict that Catalyst Pharmaceuticals's Revenue will grow at a rate of 45.86%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$44.70 | Buy/Sell | $58.15 | 21.92% |
| REGN Stock Forecast | Regeneron Pharmaceuticals | Outperform |
2
|
$890.68 | Buy/Sell | $961.26 | 17.89% |
| ZTS Stock Forecast | Zoetis | Outperform |
18
|
$153.36 | Buy/Sell | $220.47 | 44.11% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$40.23 | Buy/Sell | $44.86 | 11.86% |
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$143.71 | Buy/Sell | $245.24 | 49.61% |
| VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$11.47 | Buy/Sell | $11.73 | 4.62% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| UTHR Stock Forecast | United Therapeutics | Outperform |
12
|
$235.95 | Buy/Sell | $284.08 | 25.87% |
| CTLT Stock Forecast | Catalent | Hold |
15
|
$55.80 | Buy/Sell | $49.29 | 13.80% |
| CYTK Stock Forecast | Cytokinetics | Outperform |
10
|
$64.80 | Buy/Sell | $87.92 | 45.06% |
Catalyst Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
Catalyst Pharmaceuticals's EBITDA has seen impressive growth In the last three years, rising from $41.40M to $119.69M – a growth of 189.11%. In the next year, analysts believe that EBITDA will reach $184.77M – an increase of 54.37%. For the next seven years, the forecast is for EBITDA to grow by 101.53%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IONS Stock Forecast | Ionis Pharmaceuticals | Outperform |
9
|
$41.84 | Buy/Sell | $55.60 | 43.88% |
| MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$194.38 | Buy/Sell | $315.92 | 100.64% |
| BCPC Stock Forecast | Balchem | Outperform |
18
|
$138.50 | Buy/Sell | $145.00 | 15.16% |
Catalyst Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Catalyst Pharmaceuticals's EBIT has grown by 110.19%, rising from $41.30M to $86.81M. For the next year, analysts predict that EBIT will reach $212.51M – an increase of 144.80%. Over the next seven years, experts believe that Catalyst Pharmaceuticals's EBIT will grow at a rate of 305.44%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PRGO Stock Forecast | Perrigo Co PLC | Outperform |
16
|
$31.27 | Buy/Sell | $44.75 | 26.64% |
| NEOG Stock Forecast | Neogen | Outperform |
16
|
$11.96 | Buy/Sell | $37.00 | 42.14% |
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£14.00 | Buy/Sell | £28.89 | 123.14% |
Catalyst Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Catalyst Pharmaceuticals's EPS has decreased from $0.40 to $0.00 – a 100.00% drop. For next year, analysts predict EPS of $1.48, which would mean an increase of 100.00%. Over the next seven years, experts predict that Catalyst Pharmaceuticals's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CORT Stock Forecast | Corcept Therapeutics | Buy |
16
|
$22.21 | Buy/Sell | $35.67 | 71.09% |
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Buy |
14
|
$8.08 | Buy/Sell | $17.83 | 110.40% |
| TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$13.91 | Buy/Sell | $29.44 | 144.43% |
Site Navigation
.jpg)